Bank of America’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-27,000
Closed -$195K 7868
2022
Q2
$195K Buy
+27,000
New +$235K ﹤0.01% 6113

Other funds holding CHRS

Bank of America's CHRS Position: Q1 2026 in Review

Bank of America increased its Coherus Oncology (CHRS) stake by 190% in Q1 2026, buying an estimated $377K and bringing the position to 324,133 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

Bank of America first reported a position in CHRS in Q1 2015 and has held it in 45 quarters since. The position peaked at $7.06M in Q4 2023. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Bank of America held 324,133 shares of Coherus Oncology worth $548K as of Q1 2026.
  • Bank of America bought 212,430 Coherus Oncology shares in Q1 2026, an estimated $377K.
  • Coherus Oncology made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4844 holding.
  • Bank of America first reported a position in Coherus Oncology in Q1 2015 and has held it in 45 quarters since.
  • Bank of America's Coherus Oncology position peaked at $7.06M in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.